In the HY2016 results announcements (released 24/2/2016), it...

In the HY2016 results announcements (released 24/2/2016), it said -

"Global dose sales increased 15.7% to 5,728 units", and

"The first half result is consistent with our dose sales objectives for the full financial year."

However, this attitude has suddenly changed somehow, as  SRX  "revised" "full year dose sales growth guidance at 15-17%" from "previously ... at least ... 19.7%" (announcement yesterday).

My questions are -

Why would a HY 15.7% increase of dose sale 3 months ago " be consistent with our dose sales objectives for the full financial year", whereas now "15-17%" increase of dose sale for the same full financial year would not?

When did SRX revised the "dose sales objectives for the full financial year" from around "15.7%" 3 months ago to "19.7%" now?  (I don't think anyone of us knows this.)

I reckon that these inconsistencies/contradictions are somewhat sinister and this may hint shockingly full year profit results.